TOP TEN perturbations for 1479_g_at (Homo sapiens)

Organism: Homo sapiens
Gene: 1479_g_at
Selected probe(set): 211339_s_at
Platform: Affymetrix Human Genome U133 Plus 2.0 Array

Expression of 1479_g_at (211339_s_at) across 6672 perturbations tested by GENEVESTIGATOR:

glioma study 17 (glioblastoma; unsorted) / non-tumor cortical tissue

Relative Expression (log2-ratio):4.52565
Number of Samples:2 / 4
Experimental glioma study 17 (glioblastoma; unsorted)
Brain cells isolated from high grade glioblastoma (grade IV). Tumor tissue was dissociated using enzymatic treatment and all cells were used for RNA isolation.
Control non-tumor cortical tissue
Cortical tissue obtained from patients with epilepsy, but without any manifested brain cancer. The tissue was dissociated using enzymatic treatment, but all brain cell types were used for analyses.

B-CLL study 11 (rolipram) / rolipram study 4 (normal T-cell; 20uM)

Relative Expression (log2-ratio):-4.3761187
Number of Samples:4 / 4
Experimental B-CLL study 11 (rolipram)
Peripheral blood mononuclear cells (PBMCs) obtained from chronic lymphocytic leukemia (CLL) patients and in vitro treated with rolipram (20 uM, cyclic nucleotide phosphodiesterase (PDE4) inhibitor) for 4 hours. PBMCs’ samples contained 90% CD19+ CD5+ B lineage CLL cells (B-CLL). Inclusion criteria: untreated CLL patients or at least 1 month after chemotherapy. Exclusion criteria: patients with active infections or other serious medical conditions or with white blood cell (WBC) counts of 15,000/l. ATC code:---
Control rolipram study 4 (normal T-cell; 20uM)
MACS purified T-cells from healthy donor peripheral blood treated with rolipram (20 uM, cyclic nucleotide phosphodiesterase (PDE4) inhibitor) for 4 hours. ATC code:---

B-CLL study 11 (DMSO) / vehicle (DMSO) treated normal T-cell sample

Relative Expression (log2-ratio):-4.2807503
Number of Samples:4 / 4
Experimental B-CLL study 11 (DMSO)
Peripheral blood mononuclear cells (PBMCs) obtained from chronic lymphocytic leukemia (CLL) patients and in vitro treated with vehicle (DMSO) for 4 hours. PBMCs’ samples contained 90% CD19+ CD5+ B lineage CLL cells (B-CLL). Inclusion criteria: untreated CLL patients or at least 1 month after chemotherapy. Exclusion criteria: patients with active infections or other serious medical conditions or with white blood cell (WBC) counts of 15,000/l.
Control vehicle (DMSO) treated normal T-cell sample
MACS purified T-cells from healthy donor peripheral blood treated with vehicle (DMSO) for 4 hours.

Sjogren's syndrome study 2 (pSS) / Sjogren's syndrome study 2 (non-pSS)

Relative Expression (log2-ratio):3.891262
Number of Samples:7 / 14
Experimental Sjogren's syndrome study 2 (pSS)
Incisional biopsy of one parotid gland of patients who fulfilled the 2002 AECG criteria for primary Sjogren's syndrome (pSS). Patients were at least 21 years old.
Control Sjogren's syndrome study 2 (non-pSS)
Incisional biopsy of one parotid gland of patients with Sicca-syndrome who did not fulfill the 2002 AECG criteria for primary Sjogren's syndrome (non-pSS Sicca). Patients were at least 21 years old.

cutaneous T-cell lymphoma study 1 (tumor phase) / normal skin tissue

Relative Expression (log2-ratio):3.7931385
Number of Samples:4 / 8
Experimental cutaneous T-cell lymphoma study 1 (tumor phase)
Lesional skin biopsies from patients with cutaneous T-cell lymphoma in the tumor phase (extranodal).
Control normal skin tissue
Skin biopsies from healthy individuals.

kidney transplantation study 11 (1 week) / normal blood sample

Relative Expression (log2-ratio):-3.6305408
Number of Samples:11 / 5
Experimental kidney transplantation study 11 (1 week)
Whole blood samples derived from kidney transplant patients 1 week post-transplantation. Samples were collected 1 week after transplantation and administration of immunosuppressive therapy (day 1-4: methylprednisolone (60 mg); 3 doses: rabbit polyclonal anti-thymocyte globulin (ThymoglobulinH; 6 mg/kg); mycophenolate mofetil (CellCeptH); and tacrolimus (PrografH).
Control normal blood sample
Blood samples derived from healthy control subjects.

B-CLL study 9 (CD19+; CD5+; untreated) / untreated normal B-cell sample (CD19+)

Relative Expression (log2-ratio):3.503417
Number of Samples:3 / 2
Experimental B-CLL study 9 (CD19+; CD5+; untreated)
Untreated CD19+ CD5+ B-cell samples from subjects with chronic lymphocytic leukemia (CLL) and cultured in B-cell media. B-cells were isolated from peripheral blood mononuclear cells. Samples were collected from predominantly chemotherapy-naive patients representing the broad spectrum of CLL clinical heterogeneity, based on established prognostic risk factors (ZAP70 expression; degree of somatic hypermutation in the variable region of the immunoglobulin heavy chain [IGHV] gene; presence of specific CLL-associated cytogenetic abnormalities). All tumor samples were comprised of more then 95% tumor purity.
Control untreated normal B-cell sample (CD19+)
Untreated CD19+ B-cell samples from normal control subjects and cultured in B-cell media. B-cells were isolated from peripheral blood mononuclear cells.

Sjogren's syndrome study 2 (pSS) / normal parotid gland tissue

Relative Expression (log2-ratio):3.4849958
Number of Samples:7 / 9
Experimental Sjogren's syndrome study 2 (pSS)
Incisional biopsy of one parotid gland of patients who fulfilled the 2002 AECG criteria for primary Sjogren's syndrome (pSS). Patients were at least 21 years old.
Control normal parotid gland tissue
Samples taken from the dorsal caudal lobe of the parotid gland from control subjects that were at least 21 years old. Samples were harvested during surgery for oral or oropharyngeal squamous cell carcinoma. Histopathologic evaluation of parotid tissue from controls revealed no carcinoma

precursor-B-ALL study 3 (PAX5-rearranged) / T-ALL study 3

Relative Expression (log2-ratio):-3.4628305
Number of Samples:6 / 29
Experimental precursor-B-ALL study 3 (PAX5-rearranged)
Peripheral blood and bone marrow samples of pediatric patients with precursor B-ALL [dic(9;20)(p11-13;q11) )/PAX5 rearranged]. Patients were part of the Nordic Society Of Pediatric Hematology And Oncology Group (NOPHO).
Control T-ALL study 3
Peripheral blood or bone marrow samples of pediatric patients with childhood T-ALL. Patients were part of the Nordic Society Of Pediatric Hematology And Oncology Group (NOPHO).

precursor-B-ALL study 3 (hyperdiploid) / T-ALL study 3

Relative Expression (log2-ratio):-3.4335775
Number of Samples:17 / 29
Experimental precursor-B-ALL study 3 (hyperdiploid)
Peripheral blood and bone marrow samples of pediatric patients with precursor B-ALL (hyperdiploidy). Patients were part of the Nordic Society Of Pediatric Hematology And Oncology Group (NOPHO).
Control T-ALL study 3
Peripheral blood or bone marrow samples of pediatric patients with childhood T-ALL. Patients were part of the Nordic Society Of Pediatric Hematology And Oncology Group (NOPHO).